Phase II clinical trial of gemcitabine plus oxaliplatin in patients with metastatic pancreatic adenocarcinoma with a family history of pancreatic/breast/ovarian/prostate cancer or personal history of breast/ovarian/prostate cancer (FABRIC study)

被引：0
|
作者：
Naohiro Okano
Chigusa Morizane
Shogo Nomura
Hideaki Takahashi
Hidetaka Tsumura
Hironaga Satake
Nobumasa Mizuno
Kunihiro Tsuji
Kazuhiko Shioji
Akinori Asagi
Kohichiroh Yasui
Sho Kitagawa
Tomomi Kashiwada
Atsushi Ishiguro
Masashi Kanai
Makoto Ueno
Takashi Ogura
Satoshi Shimizu
Kazutoshi Tobimatsu
Masayo Motoya
Koji Nakashima
Masafumi Ikeda
Takuji Okusaka
Junji Furuse
机构：
[1] Kyorin University Faculty of Medicine,Department of Medical Oncology
[2] National Cancer Center Hospital,Department of Hepatobiliary and Pancreatic Oncology
[3] National Cancer Center,Biostatistics Division, Center for Research Administration and Support
[4] National Cancer Center Hospital East,Department of Hepatobiliary and Pancreatic Oncology
[5] Hyogo Cancer Center,Department of Gastroenterology
[6] Kobe City Medical Center General Hospital,Department of Medical Oncology
[7] Aichi Cancer Center Hospital,Department of Gastroenterology
[8] Ishikawa Prefectural Central Hospital,Department of Gastroenterology
[9] Niigata Cancer Center Hospital,Department of Internal Medicine
[10] National Hospital Organization Shikoku Cancer Center,Department of Gastrointestinal Medical Oncology
[11] Kyoto Prefectural University of Medicine,Department of Gastroenterology and Hepatology
[12] Sapporo Kosei General Hospital,Department of Gastroenterology
[13] Saga University,Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine
[14] Teine Keijinkai Hospital,Department of Medical Oncology
[15] Kyoto University,Department of Medical Oncology, Graduate School of Medicine
[16] Kanagawa Cancer Center,Department of Gastroenterology, Hepatobiliary and Pancreatic Medical Oncology Division
[17] St. Marianna University School of Medicine,Department of Clinical Oncology
[18] Saitama Cancer Center,Department of Gastroenterology
[19] Kobe University Graduate School of Medicine,Division of Gastroenterology, Department of Internal Medicine
[20] Sapporo Medical University School of Medicine,Department of Gastroenterology and Hepatology
[21] University of Miyazaki Hospital,Department of Clinical Oncology
来源：
International Journal of Clinical Oncology | 2020年 / 25卷
关键词：
Pancreatic cancer; Gemcitabine; Oxaliplatin; Platinum compounds;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1835 / 1843
页数：8
相关论文
共 50 条
  • [31] Cetuximab plus gemcitabine/oxaliplatin (GEMOXCET) in first-line metastatic pancreatic cancer: a multicentre phase II study
    F Kullmann
    S Hollerbach
    M M Dollinger
    J Harder
    M Fuchs
    H Messmann
    J Trojan
    E Gäbele
    A Hinke
    C Hollerbach
    E Endlicher
    British Journal of Cancer, 2009, 100 : 1032 - 1036
  • [32] Bevacizumab plus gemcitabine and oxaliplatin as first-line therapy for metastatic or locally advanced pancreatic cancer: a phase II trial
    Fogelman, David
    Jafari, Mehrdad
    Varadhachary, Gauri R.
    Xiong, Henry
    Bullock, Susie
    Ozer, Harold
    Lin, E.
    Morris, Jeffrey
    Cunningham, Patti
    Bennett, Bronwyn
    Abbruzzese, James L.
    Wolff, Robert A.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2011, 68 (06) : 1431 - 1438
  • [33] Phase II study of gemcitabine plus cisplatin in patients with metastatic breast cancer - A north central cancer treatment group trial
    Burch, PA
    Mailliard, JA
    Hillman, DW
    Perez, EA
    Krook, JE
    Rowland, KM
    Veeder, MH
    Cannon, MW
    Ingle, JN
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2005, 28 (02): : 195 - 200
  • [34] A phase II trial of gemcitabine in combination with oxaliplatin and capecitabine in previously untreated metastatic or recurrent pancreatic cancer
    Sym, Sun Jin
    Hong, Junsik
    Jung, Minkyu
    Koo, Yang Seo
    Park, Yeon Ho
    Kim, Koen Kook
    Park, Jinny
    Cho, Eun Kyung
    Lee, Jae Hoon
    Shin, Dongbok
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)
  • [35] PROSTATE, OVARIAN, AND UTERINE-CANCER FAMILY HISTORY AND FAMILIAL BREAST-CANCER AGE-SPECIFIC RISKS
    BADZIOCH, MD
    ANDERSON, DE
    AMERICAN JOURNAL OF HUMAN GENETICS, 1993, 53 (03) : 272 - 272
  • [36] Gemcitabine, oxaliplatin, and capecitabine (GEMOXEL) compared with gemcitabine alone in metastatic pancreatic cancer: a randomized phase II study
    Roberto Petrioli
    Giandomenico Roviello
    Anna Ida Fiaschi
    Letizia Laera
    Daniele Marrelli
    Franco Roviello
    Edoardo Francini
    Cancer Chemotherapy and Pharmacology, 2015, 75 : 683 - 690
  • [37] A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer
    Oettle, H
    Richards, D
    Ramanathan, RK
    van Laethem, JL
    Peeters, M
    Fuchs, M
    Zimmermann, A
    John, W
    Von Hoff, D
    Arning, M
    Kindler, HL
    ANNALS OF ONCOLOGY, 2005, 16 (10) : 1639 - 1645
  • [38] Gemcitabine, oxaliplatin, and capecitabine (GEMOXEL) compared with gemcitabine alone in metastatic pancreatic cancer: a randomized phase II study
    Petrioli, Roberto
    Roviello, Giandomenico
    Fiaschi, Anna Ida
    Laera, Letizia
    Marrelli, Daniele
    Roviello, Franco
    Francini, Edoardo
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015, 75 (04) : 683 - 690
  • [39] PROSTATE CANCER RISK IN MEN WITH PROSTATE AND BREAST CANCER FAMILY HISTORY: RESULTS FROM THE REDUCE STUDY
    Thomas, Jean-Alfred
    Gerber, Leah
    Moreira, Daniel M.
    Hamilton, Robert J.
    Banez, Lionel L.
    Castro, Ramiro S.
    Andriole, Gerald L.
    Isaacs, William B.
    Xu, Jianfeng
    Freedland, Stephen J.
    JOURNAL OF UROLOGY, 2012, 187 (04): : E66 - E66
  • [40] Risk of ovarian cancer in breast-cancer patients with a family history of either - Reply
    Bergfeldt, K
    Hall, P
    LANCET, 2003, 361 (9352): : 179 - 180
12345